LENZ Therapeutics (NASDAQ:LENZ) today reported its financial results for the fourth quarter and full year ended December 31, 2025, providing the first comprehensive look at the commercial performance of VIZZ® (aceclidine 1.44%).
Since its U.S. commercial launch in October 2025, the preservative-free, once-daily eye drop for the treatment of presbyopia has seen rapid adoption.
Q4 product revenue totaled $1.6 million, a figure that reflects the initial two months of market availability and an aggressive rollout strategy targeting the millions of U.S. adults seeking alternatives to reading glasses.
The company’s "early launch" metrics indicate a robust trajectory for 2026.
LENZ reported that over 45,000 paid prescriptions have been processed through the first quarter of 2026, driven by broad prescriber uptake across both optometry and ophthalmology channels.
To sustain this momentum, LENZ is expanding its specialized sales footprint to 117 territories, a deployment expected to be fully completed by the end of Q2 2026.
This expansion aims to capture a larger share of the "near-vision" market, which remains significantly underserved following the discontinuation or limited adoption of earlier-generation miotics.
Financially, LENZ maintains one of the strongest balance sheets in the mid-cap ophthalmic sector.
As of December 31, 2025, the company held $292.3 million in cash and marketable securities.
This substantial liquidity provides a multi-year runway to support the ongoing U.S. commercial scale-up and its newly initiated international expansion.
In March 2026, the company achieved a major global milestone by submitting a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA), seeking approval for VIZZ® in the European Union.
Strategic partnerships are also fueling the company's ex-U.S. strategy.
LENZ announced several new international agreements to leverage local expertise in key Asian and Latin American markets, ensuring a coordinated global rollout.